A Diabetes Drug Called Invokana May Prevent or Slow Kidney Disease, a New Study Says
A drug that’s used to help control blood sugar in people with diabetes has now been shown to help prevent or slow kidney disease, which causes millions of deaths each year and requires hundreds of thousands of people to use dialysis to stay alive.
Doctors say it’s hard to overstate the importance of this study, and what it means for curbing this problem, which is growing because of the obesity epidemic.
The study tested Janssen Pharmaceuticals’ drug Invokana. Results were discussed Sunday at a medical meeting in Australia and published by the New England Journal of Medicine.
About 30 million Americans and...
Source: TIME: Health - April 15, 2019 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized medicine onetime overnight Source Type: news
Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA ® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 28, 2019 Category: Pharmaceuticals Source Type: news
Diabetes drug alters vitamin D levels, possibly explaining increased bone fracture risk
Scientists found that the diabetes drug canagliflozin reduces vitamin D levels and calcium uptake, which may explain why this drug can increase the risk of bone fractures. (Source: NIDDK News)
Source: NIDDK News - March 22, 2019 Category: Endocrinology Source Type: news
CANVAS: Reassuring Data on Stroke With Canagliflozin CANVAS: Reassuring Data on Stroke With Canagliflozin
More detailed data from the CANVAS program have been reported showing reassuring results on all stroke types and a significant reduction in hemorrhagic stroke.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 9, 2019 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Type 2 Diabetes Med Might Not Harm Bones After All
Canagliflozin (Invokana, Invokamet) is in a class of medications called SGLT-2 inhibitors. These drugs cause the kidneys to remove excess sugar from the blood and excrete it through urine, which lowers blood sugar levels. This class of drugs has been linked to a number of complications, including kidney injury and serious genital infections. (Source: WebMD Health)
Source: WebMD Health - January 3, 2019 Category: Consumer Health News Source Type: news
Study Eases Concern That Common Diabetes Drug Canagliflozin (Invokana, Invokamet) Might Harm Bones
THURSDAY, Jan. 3, 2019 -- If you have type 2 diabetes and you ' re taking canagliflozin to help control your blood sugar, a new study has some good news for you: The drug doesn ' t appear to raise the risk of bone fractures.
Previously, research had... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 3, 2019 Category: General Medicine Source Type: news
Study Eases Concern That Common Diabetes Med, Canagliflozin (Invokana, Invokamet), Might Harm Bones
THURSDAY, Jan. 3, 2019 -- If you have type 2 diabetes and you ' re taking canagliflozin to help control your blood sugar, a new study has some good news for you: The drug doesn ' t appear to raise the risk of bone fractures.
Previously, research had... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 3, 2019 Category: General Medicine Source Type: news
No Increased Fracture Risk With Canagliflozin in Type 2 Diabetes
WEDNESDAY, Jan. 2, 2019 -- Canagliflozin is not associated with increased fracture risk versus glucagon-like peptide-1 (GLP-1) agonists for middle-aged patients with type 2 diabetes, according to a study published online Jan. 1 in the Annals of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 2, 2019 Category: Pharmaceuticals Source Type: news
Canagliflozin does not increase fracture risk in diabetes patients
Canagliflozin treatment does not increase the risk of fractures in type-2 diabetes patients, according to research published inAnnals of Internal Medicine.MedicalXpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 2, 2019 Category: Endocrinology Source Type: news
Canagliflozin Not Linked to Fractures in Large Database Study Canagliflozin Not Linked to Fractures in Large Database Study
Risk associated with SGLT2 inhibitor may be limited to patients with type 2 diabetes who have additional fracture risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 31, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Canagliflozin not associated with increased risk for fracture
(American College of Physicians) Compared with a glucagon-line peptide-1 (GLP-1) agonist, canagliflozin was not associated with an increased risk for fracture in patients with type 2 diabetes at relatively low risk for fracture. Findings from a multidatabase cohort study are published in Annals of Internal Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 31, 2018 Category: International Medicine & Public Health Source Type: news
Nov 2, 2018 This Week in Cardiology Nov 2, 2018 This Week in Cardiology
CV outcomes in patients with type 2 diabetes, canagliflozin, cardiorespiratory fitness, the value of randomized trials, and the most important paper of 2018 are reviewed in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 2, 2018 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Questions Raised About Invokana Label Expansion For CV Risk Reduction
Experts are raising questions about FDA ' s decision to expand the label of the diabetes drug Invokana to reduce the risk of cardiovascular events. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 1, 2018 Category: Pharmaceuticals Authors: Larry Husten, Contributor Tags: NYSE:LLY NYSE:JNJ Source Type: news
Canagliflozin (Invokana) Gets FDA Nod for CV Protection Canagliflozin (Invokana) Gets FDA Nod for CV Protection
The SGLT2 inhibitor is the first oral diabetes medication approved to reduce the risk of cardiovascular events in patients with type 2 diabetes and heart disease.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 31, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
